Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)
A biopharmaceutical company building an oncology business by developing and commercializing innovative therapies that target the molecular mechanisms implicated in cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
shorrrttttt
Recs
Possible takeover target
Recs
Bayer's buyout target. $18 is a fair price to sell.
Recs
This company will do so well in the near future
Recs
I like drugs and I like them cheap. The company makes generic drugs! Yeah they had a set back, but who cares, there's plenty of sick (and not so sick) people who want their drugs!
Recs
Oversold on FDA rejection of liver drug application for skin cancer. Firm has strong sales growth on its current cancer drugs and two major applications in the pipeline.
Bayer is strong partner.
Recs
Recent trial failure is a Buy opportunity. Still many more trials pending.
Recs
Buy Low, Sell High
Recs
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar®, a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar has been approved for the treatment of advanced kidney cancer.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 61 - 69 of 69 : « Previous 1 2 3 4